Testing an AI tool that grades stomach lining changes during endoscopy
Checks an AI tool for grading gastric intestinal metaplasia in people having stomach endoscopy.
Plain-language title generated from the registry record
Registry title: Multi-center Prospective Validation of Real-Time AI-EGGIM System
Key facts
- Where
- Binzhou, Jinan, and Qingdao, ChinaSee the 3 sites
Where in China
- Shandong Medical and Pharmaceutical University HospitalBinzhou, ChinaNo longer taking part
- Qilu Hospital of Shandong UniversityJinan, ChinaNo longer taking part
- Qilu Hospital of Shandong University (Qingdao)Qingdao, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qilu Hospital of Shandong University
- Trial code
- NCT07915843
- Record updated
- 4 November 2026
- Original description
Gastric intestinal metaplasia (GIM) is a precancerous condition associated with an increased risk of gastric cancer. The endoscopic grading of gastric intestinal metaplasia (EGGIM) score evaluates the extent of GIM across five standard gastric regions. The investigators developed a real-time artificial intelligence-assisted EGGIM (AI-EGGIM) system that automatically assigns an intestinal metaplasia grade to each region and calculates a total EGGIM score.Read full original descriptionShow less
Prospective Multi-center Validation of a Real-Time Artificial Intelligence-Assisted EGGIM System for Gastric Cancer Stratification
Gastric intestinal metaplasia (GIM) is a precancerous condition associated with an increased risk of gastric cancer. The endoscopic grading of gastric intestinal metaplasia (EGGIM) score evaluates the extent of GIM across five standard gastric regions. The investigators developed a real-time artificial intelligence-assisted EGGIM (AI-EGGIM) system that automatically assigns an intestinal metaplasia grade to each region and calculates a total EGGIM score.
This prospective multi-center validation study will consecutively enroll patients undergoing upper gastrointestinal endoscopy. The AI-EGGIM system will generate real-time grades for the five standard gastric regions. Regardless of endoscopic appearance or AI output, every patient will undergo five mapping biopsies, with one biopsy obtained from each standard region. Histopathological operative link on gastric intestinal metaplasia (OLGIM) staging will serve as the reference standard. The primary objective is to estimate the performance of an AI-EGGIM score ≥ 5 for identifying patients at high risk of gastric cancer.
Inclusion: patients undergoing upper gastrointestinal endoscopy who met at least one of the following criteria: (i) aged 40-75 years; or (ii) had a history of H. pylori infection and/or known premalignant gastric lesions (e.g., atrophic gastritis and IM); patients who voluntarily sign the informed consent form.
Exclusion: patients with previous surgical procedures on the stomach; patients with severe cardiac, cerebral, pulmonary, or renal dysfunction or psychiatric disorders who cannot receive upper gastrointestinal endoscopy; patients with upper gastrointestinal cancer; patients with contraindication to gastric mucosal biopsy.